Literature DB >> 22872019

Parvovirus B19 myocarditis causes significant morbidity and mortality in children.

Kimberly M Molina1, Xiomara Garcia, Susan W Denfield, Yuxin Fan, William R Morrow, Jeffrey A Towbin, Elizabeth A Frazier, David P Nelson.   

Abstract

Although parvovirus B19 (PVB19) currently is the most common cause of viral myocarditis, limited pediatric data exist. Whereas other viruses infect cardiomyocytes, PVB19 targets coronary endothelium, leading to myocardial ischemia and dysfunction. A retrospective review investigated patients with polymerase chain reaction (PCR)-verified PVB19 myocarditis at Texas Children's Hospital and Arkansas Children's Hospital (January 2005 to August 2008). The primary end points of the study were transplant-free survival and circulatory collapse (death, mechanical support, or transplantation). For the 19 patients identified (age, 6 months to 15 years), the most common presenting symptoms were respiratory and gastrointestinal. At admission, all the patients demonstrated ventricular dysfunction requiring inotropic support (median ejection fraction, 24 %; median left ventricle end-diastolic diameter [LVEDD] z-score, 4.6). Whereas T-wave abnormalities were common, ST elevation was evident in five patients (two died and three required transplantation). Serum B-type natrietic peptide was elevated in all 12 patients tested (range, 348-8,058 pg/ml), and troponin I was high in 7 of 9 patients (range, 0.04-14.5 ng/ml). Of the 15 patients with circulatory collapse, nine received mechanical support, eight underwent successful transplantation, and five died. Only six patients (32 %) experienced transplant-free survival, and five patients had full recovery of function at discharge. In the transplant-free survival group, ST changes on presenting electrocardiography were less likely (p = 0.03), and the admission LVEDD z-score tended to be lower (3.3 vs 5.6; p = 0.08). In children, PVB19 myocarditis causes significant mortality and morbidity. Although mechanical intervention can support patients in the initial stage of decompensated heart failure, patients with PVB19 myocarditis often demonstrate persistent dysfunction requiring medical therapy and transplantation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22872019     DOI: 10.1007/s00246-012-0468-4

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN: 0172-0643            Impact factor:   1.655


  28 in total

Review 1.  Myocarditis.

Authors:  A M Feldman; D McNamara
Journal:  N Engl J Med       Date:  2000-11-09       Impact factor: 91.245

Review 2.  Parvovirus B19.

Authors:  Neal S Young; Kevin E Brown
Journal:  N Engl J Med       Date:  2004-02-05       Impact factor: 91.245

3.  NT-pro BNP in acute childhood myocarditis.

Authors:  Elisabeth Mlczoch; Farnaz Darbandi-Mesri; Doris Luckner; Ulrike Salzer-Muhar
Journal:  J Pediatr       Date:  2011-10-11       Impact factor: 4.406

4.  Presentation, patterns of myocardial damage, and clinical course of viral myocarditis.

Authors:  Heiko Mahrholdt; Anja Wagner; Claudia C Deluigi; Eva Kispert; Stefan Hager; Gabriel Meinhardt; Holger Vogelsberg; Peter Fritz; Juergen Dippon; C-Thomas Bock; Karin Klingel; Reinhard Kandolf; Udo Sechtem
Journal:  Circulation       Date:  2006-10-02       Impact factor: 29.690

5.  A case of fetal parvovirus B19 myocarditis, terminal cardiac heart failure, and perinatal heart transplantation.

Authors:  C S von Kaisenberg; G Bender; J Scheewe; S W Hirt; M Lange; J Stieh; H H Kramer; W Jonat
Journal:  Fetal Diagn Ther       Date:  2001 Nov-Dec       Impact factor: 2.587

6.  Active, fulminant, lethal myocarditis associated with parvovirus B19 infection in an infant.

Authors:  Nikos Papadogiannakis; Thomas Tolfvenstam; Björn Fischler; Oscar Norbeck; Kristina Broliden
Journal:  Clin Infect Dis       Date:  2002-10-11       Impact factor: 9.079

7.  Management and outcomes in pediatric patients presenting with acute fulminant myocarditis.

Authors:  Sarah A Teele; Catherine K Allan; Peter C Laussen; Jane W Newburger; Kimberlee Gauvreau; Ravi R Thiagarajan
Journal:  J Pediatr       Date:  2010-12-30       Impact factor: 4.406

8.  Childhood myocarditis and parvovirus B19 genotypes.

Authors:  Julia Dina; Florence Villedieu; Fabien Labombarda; François Freymuth; Geoffroy de la Gastine; Mikael Jokic; Astrid Vabret
Journal:  J Clin Virol       Date:  2010-10-16       Impact factor: 3.168

9.  Fatal parvovirus B19 myocarditis in children and possible dysimmune mechanism.

Authors:  Berengere Koehl; Mehdi Oualha; Fabrice Lesage; Caroline Rambaud; Danielle Canioni; Philippe Hubert; Marianne Leruez-Ville
Journal:  Pediatr Infect Dis J       Date:  2012-04       Impact factor: 2.129

10.  High prevalence of viral genomes and multiple viral infections in the myocardium of adults with "idiopathic" left ventricular dysfunction.

Authors:  Uwe Kühl; Matthias Pauschinger; Michel Noutsias; Bettina Seeberg; Thomas Bock; Dirk Lassner; Wolfgang Poller; Reinhard Kandolf; Heinz-Peter Schultheiss
Journal:  Circulation       Date:  2005-02-07       Impact factor: 29.690

View more
  14 in total

1.  Risk Factors for Cardiac Arrest or Mechanical Circulatory Support in Children with Fulminant Myocarditis.

Authors:  Joseph R Casadonte; Mjaye L Mazwi; Katheryn E Gambetta; Hannah L Palac; Mary E McBride; Osama M Eltayeb; Michael C Monge; Carl L Backer; John M Costello
Journal:  Pediatr Cardiol       Date:  2016-11-08       Impact factor: 1.655

2.  Human parvovirus B19: a mechanistic overview of infection and DNA replication.

Authors:  Yong Luo; Jianming Qiu
Journal:  Future Virol       Date:  2015       Impact factor: 1.831

3.  Structure of Parvovirus B19 Decorated by Fabs from a Human Antibody.

Authors:  Yingyuan Sun; Thomas Klose; Yue Liu; Susanne Modrow; Michael G Rossmann
Journal:  J Virol       Date:  2019-04-17       Impact factor: 5.103

Review 4.  Human Parvoviruses.

Authors:  Jianming Qiu; Maria Söderlund-Venermo; Neal S Young
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

5.  Parvovirus B19 myocarditis in children: a diagnostic and therapeutic approach.

Authors:  Roger Esmel-Vilomara; Paola Dolader; Jaume Izquierdo-Blasco; Joan Balcells; Moisés Sorlí; Fuensanta Escudero; Elena Vera; Ferran Gran
Journal:  Eur J Pediatr       Date:  2022-02-09       Impact factor: 3.183

Review 6.  Myocarditis Following COVID-19 Vaccine Use: Can It Play a Role for Conditioning Immunization Schedules?

Authors:  Susanna Esposito; Caterina Caminiti; Rosanna Giordano; Alberto Argentiero; Greta Ramundo; Nicola Principi
Journal:  Front Immunol       Date:  2022-06-27       Impact factor: 8.786

Review 7.  Myocarditis in Paediatric Patients: Unveiling the Progression to Dilated Cardiomyopathy and Heart Failure.

Authors:  Inês Teixeira Farinha; Joana Oliveira Miranda
Journal:  J Cardiovasc Dev Dis       Date:  2016-11-08

8.  The highest mortality rates in childhood dilated cardiomyopathy occur during the first year after diagnosis.

Authors:  Shalan Fadl; Håkan Wåhlander; Katja Fall; Yang Cao; Jan Sunnegårdh
Journal:  Acta Paediatr       Date:  2017-12-26       Impact factor: 2.299

9.  Myopathic Cardiac Genotypes Increase Risk for Myocarditis.

Authors:  Amy R Kontorovich; Nihir Patel; Arden Moscati; Felix Richter; Inga Peter; Enkhsaikhan Purevjav; Simina Ramona Selejan; Ingrid Kindermann; Jeffrey A Towbin; Michael Bohm; Karin Klingel; Bruce D Gelb
Journal:  JACC Basic Transl Sci       Date:  2021-07-26

10.  The Impact of Specific Viruses on Clinical Outcome in Children Presenting with Acute Heart Failure.

Authors:  Maria Giulia Gagliardi; Alessandra Fierabracci; Mara Pilati; Marcello Chinali; Carlo Bassano; Francesca Saura; Isabella Giovannoni; Paola Francalanci
Journal:  Int J Mol Sci       Date:  2016-04-01       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.